Canine granulocyte-macrophage colony-stimulating factor (caGM-CSF) was cloned and eKpressed to allow further investigation of GM-CSF in a large animal model. The cDNA is 850 base pairs (bp) long and encodes a peptide of 144 amino acids. The nucleotide and amino acid sequence homology between caGM-CSF and human GM-CSF (hGM-CSF) is 80% and 70%. respectively. A mammalian expression vector pCMV/CAGM was constructed and used to transfect COS cells for expression of caGM-CSF. Supernatant from transfected COS cells enriched with caGM-CSF was shown to have significant stimulating activity in granulocyte-macrophage colony forming unit (CFU-GM) assays of canine mar-RANULOCYTE-macrophage colony-stimulating fac-G tor (GM-CSF) is a glycoprotein that regulates proliferation and differentiation of hematopoietic progenitors.'rZ It is produced by lymphocytes, monocytes, endothelial cells, and fibroblasts, as well as other cell lineages? It has broad stimulating activity in vitro on hematopoietic cells, alone or in combination with other hematopoietic growth factor^.'^^"
It also alters the function of relatively differentiated cells such as neutrophils and macrophages by enhancing chemotaxis and increasing oxidative metabolism, phagocytic activity, and microbicidal a~tivity.'~-'~ In vivo studies became possible with isolation of the cDNA for GM-CSF and production of recombinant Animal studies and clinical trials have been completed and suggest a potential therapeutic effect for GM-CSF, but biologic and preclinical questions persist about the role of this factor in control of hematopoiesis and the optimum use either alone or in combination to reverse perturbations of hematopoiesis secondary to a disease process or to toxicity of radiation and chemotherapy.
Experimental models of bone marrow transplantation (BMT) as well as studies of the radiobiology of hematopoiesis are well established in dogs.3336 This animal model therefore would be useful for study of the in vivo role of supraphysiologic doses of hematopoietic growth factors row. caGM-CSF, expressed from bacteria, was used to treat seven dogs at varying doses twice daily subcutaneously (sc) for 14 to 16 days. Circulating blood neutrophils and monocytes increased significantly. The increase in circulating eosinophils was variable. Thrombocytopenia developed during administration of caGM-CSF but corrected rapidly after cessation of treatment. Evaluation of survival times of 5'Crlabeled autologous platelets suggested increased consumption as the primary reason for thrombocytopenia. A speciesspecific GM-CSF will be a useful tool for hematologic or immunologic studies in dogs. 0 1991 by The American Society of Hematology.
such as GM-CSF. Cloning of the cDNA for GM-CSF from three species-mouse, ' and humans2-has been reported. The biologic activity of GM-CSF has been demonstrated to be species-restricted to varying degrees despite a significant nucleotide and amino acid sequence homolMurine GM-CSF does not stimulate human hematopoietic cells, and human GM-CSF (hGM-CSF) does not stimulate murine hematopoietic cells. Bovine GM-CSF had a markedly reduced stimulatory effect on human and murine cells as compared with their respective speciesspecific factors.37 hGM-CSF was demonstrated to stimulate canine hematopoiesis in in vitro assays, however. Activity in vivo was demonstrated by administering pharmacologic doses to dogs?8 Thrombocytopenia was observed in all dogs that received hGM-CSF. The possibility that this was an unpredicted effect of administering a xenogeneic hematapoietic growth factor was considered. Xenogeneic proteins are also more likely to be immunogenic. In addition, the relative activity of hGM-CSF as compared with canine GM-CSF (caGM-CSF) in the dog experimental model was unknown. For these reasons, further in vivo studies to define the biologic activities of GM-CSF in a canine model required the species-specific factor for proper interpretation. We report the cloning and expression of the cDNA for caGM-CSF as well as initial studies of the biologic activity of the recombinant protein.
MATERIALS AND METHODS
To obtain a T-lymphocyte-enriched population, peripheral blood and splenic mononuclear cells were isolated from a Ficoll-Hypaque gradient. They were then cultured for 48 hours in RPMI 1640 medium (M.A.
Bioproducts, Walkendle, MD) supplemented with 5% fetal calf serum (FCS; GIBCO Grand Island, NY) with 1% phytohemagglutinin (PHA, Difco, Detroit, MI) and 5% pokeweed mitogen (GIBCO). Blast morphology was determined microscopically in all cultures to confirm stimulation of T lymphocytes before RNA extraction on a cesium chloride gradient." A cDNA library in a Lambda Zap cloning vector (Stratagene, La Jolla, CA)@ was constructed and packaged. The library was screened with the cDNA for the coding region of hGM-CSF (Genetics Institute, Cambridge, MA). Probes were radiolabeled using random hexamers and ["PI a-deoxy-cytidine triph~sphate.~' Hybridization was performed in a buffer containing 35% (volivol) formamide at 37°C Isolation offill-length caGM-CSF cDNA. A library of canine genomic DNA. partially digested with Mho 1 and ligated into EMBL4 was obtained (Clontech. Palo Alto. CA). It was screened with a radiolabeled cDNA" for caGM-CSF. The filters were hybridized with 50ri (vol/vol) formamide at 42°C. and the washes were performed at 42°C. The genomic DNA inserts were excised by Sal I and then restriction mapped. A restriction fragment with Sa/ 1/RamHI cohesive ends that hybridized with the caGM-CSF cDNA was subcloned into pBluescript SK( -).
A full-length cDNA for caGM-CSF was made by first producing a template for exon 1 from the gene through amplification by the polymerase chain reaction (PCR).'? A second PCR was then performed with two DNA templates: the exon I amplimer and the partial cDNA for caGM-CSF. These two templates had overlapping complementary sequences 80 base pairs (hp) long. The primer-linkers (20 hplBanrH1) were oligonucleotides with complementation to a region at the start codon of exon I and a region at the stop codon of the partial cDNA. In both amplification reactions, the annealing temperature was 55°C for 2 minutes. This created the full-length 432-bp coding region for the cDNA of caGM-CSF flanked by sequences for BamlIl restriction sites (Fig   1 ) .
Clones were sequenced in pBluescript SK( -) using the dideoxynucleotide method" as described in the Sequenase (United States Biochemical. Cleveland, OH) protocol for double-stranded DNA. All pBluescript SK( -) clones with the cDNA or genomic fragment inserts were initially sequenced from the flanking T3 and T7 primers. Sequence analysis was done with Genepro Version 4.2 software (Riverside Scientific Enterprises. Bainhridge Island, WA).
Genomic DNA was isolated from canine peripheral blood mononuclear cells (PBMNCs) as has been described."' Restriction digests were performed and DNA was electrophoresed in a 1.0% agarose gel. Southern transfer was done onto a nylon filter and hybridized with a "P-labeled canine GM-CSF probe.
The full-length caGM-CSF cDNA with flanking RamHl sites was subcloned into a mammalian expression vector, pCMV," which had the neo gene removed. Correct orientation of the insert was determined by A t I restriction digest. for which there was one unique site in the cDNA. The pCMV/CAGM vector was sequenced with sequence-specific Genomic DNA nna/vsi.s.
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primers for caGM-CSF. The vector was then transfected into COS cells by the calcium phosphate precipitation method.'' Cells were grown as described previously.~ and supernatant was harvested at 72 and 120 hours.
Canine colony-forming unit granulocyte-macrophage (caCFU-GM) assays were performed as described previously" with dilutions of supernatant from COS cells transfected with pCMV/ CAGM. Supernatant harvested from COS cells that had not been transfected served as one of the negative controls. Positive controls were CFU-GM assays performed with postendotoxin dog serum or human plasma that had been screened for activity in canine CFU-GM colony assays. Marrow mononuclear cells were collected from a Ficoll-Hypaque gradient. Monocyte depletion was achieved by incubation with carbonyl iron followed by magnetic separation and plastic adherence. T cells were removed by panning cells over flasks treated with canine-specificThy 1 antibody. Marrow mononuclear cells were then cultured at 7.5 x 1O'cells per plate for 10 days at 3PC in a humidified 10% CO, incubator in 35-mm plastic Petri dishes containing 2 mLagar medium. Agar medium consisted of an equal volume mixture of 0.6% (wt/vol) Bacto-Agar (Difco) and double-strength Dulhecco's modified Eagle's medium (DMEMs; GIBCO) containing 40% (vol/vol) heat-inactivated FCS.
After the recombinant protein in COSsupernatant was demonstrated to have activity on canine CFU-GM, larger quantities were produced for in vivo studies (Amgen, Thousand Oaks, CA). Canine GM-CSF was expressed as inclusion bodies in Escherichia coli using a plasmid containing a Kanamycin-resistance gene, a par locus, plasmid genes necessary for DNA replication. a transcription termination site, a ribosome binding site, and the phage A promoter.'' The GM-CSF-containing inclusion bodies were solubilized and allowed to oxidize." caGM-CSF was then purified by precipitation and cation-exchange chromatography. The protein was approximately 9WF pure as analyzed on SDSpolyacryamide gel electrophoresis (PAGE) and had endotoxin levels less than 2.5 endotoxin UlmL as determined by the limulus amebocyte lysate assay (Associates of Cape Cod, Woods Hole, MA).
Seven normal dogs were treated with caGM-CSF subcutaneously (sc) twice daily. Two dogs received 10 pgkg per day for 14 days and two other dogs received 10 pgkg per day for 16 days. The other three dogs were treated with 1,30, and 50 Fgkg per day for 14 days. Baseline PB counts were established by two measurements before administration, and counts were followed daily thereafter. Marrow aspirations and biopsies were obtained as previously described" before and after treatment. Platelet survival studies with "Cr-labeled autologous platelets were made of two dogs. one br vivoaana/eti.s. All dogs were dewormed and vaccinated for rabies, distemper leptospirosis, hepatitis, and parvovirus. They were housed in an American Association for Accreditation of Laboratory Animal Care-approved facility in standard indoor runs and received commercial dog chow and chlorinated tap water ad libitum. Animal holding areas were maintained at 70°F 2 2°F with 50% 210% relative humidity using at least 15 air changes per hour of 100% conditioned fresh air. The dogs were on a 12-hour lightidark full-spectrum lighting cycle with no twilight. The protocol for this study was approved by the internal animal use committee of the Fred Hutchinson Cancer Research Center.*
RESULTS
The cDNA library constructed from canine PB and splenic mononuclear cells had 3 x lo6 recombinants. Only three unique clones were isolated, all of which were incomplete cDNAs of caGM-CSF. After all clones were characterized by sequencing, it was evident that they were all incomplete at the 5' end. To obtain the remaining sequence, the incomplete cDNA for caGM-CSF was "P-labeled and used to screen a canine genomic library.
A genomic clone with a 12-kilobase (kb) insert was isolated. A 4.5-kb BamHI-Sal I restriction fragment from
This fragment was subcloned into pBluescript Sk(-) for sequencing. A primer derived from the sequence of the 5'
Isolation of full-length caGM-CSF cDNA clone.
the 'lone was identified as having the caGM-CSF gene'
beween GM-CSF of dogs and that of humans, cows, and mice is 70%, 71%, and 53%, respectively. The comparison indicates that a 17-amino acid region typical of signal end Of the longest incomplete cDNA previously isolated allowed sequencing Of exon I, completing the sequence for sequences precedes Ala-18 at the amino terminus of the mature polypeptide. The positions of the cysteine residues that are sites of disulfide bonds stabilizing secondary structure are conserved. There is one possible N-glycosylation site on CaGM-CSF, as compared with two on each of the full-length cDNA. A full-length cDNA for the coding region Of caGM-CSF was produced by PCR amplification Of exon I and the longest incomp1ete cDNA 'lone. The PCR product Of this the other species. The N-glycosylation sites on murine reaction was subcloned into pCMV, a mammalian expression vector with a CMV promoter. Four of these subclones were sequenced. Nucleotide misincorporation from the amplification reaction was noted in three of the four subclones. Each of these three subclones had 1-, 2-, and 5-bp misincorporations, some of which were common to at least two subclones. The fourth clone had no misincorporations and was used to express the peptide for in vitro studies.
The nucleotide sequence for caGM-CSF is shown in Fig  2. An open reading frame begins with the start codon ATG and ends at the stop codon TGA, which is 432 bp long and has an 80% sequence homology with hGM-CSF. A 17-bp sequence includes the start codon common to all four species from which GM-CSF has been isolated. The 3' region includes AT-rich sequences containing an A'ITTA sequence motif. This feature is noted on other lymphokines, cytokines, and protooncogenes.
A comparison of all known amino acid sequences of GM-CSF is summarized in Fig 3. The degree of homology GM-CSF are positioned differently as compared with the other three wes. Of the mo regions associated with function in hGM-csF,50,51 the stretch from 95 to 111 amino For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
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acids appcars to be thc most highly conserved portion to caGM-CSF. Caninc genomic DNA was rcstriction digcstcd, and a Southcrn blot was probcd with "P-labclcd caGM-CSF. Singlc hybridizing bands wcrc notcd in lancs with DNA digcstcd with RamHl + EcoRl at approximatcly 9 and 23 kb, rcspcctivcly. This suggcsts that thc gcnc for canine GM-CSF is singlc copy as has been shown for othcr species. In othcr lanes, thcrc wcrc two hybridizing bands, suggesting singlc intcrnal rcstriction sites in thc gcnc for Rg/ I, Hindlll, and A t I.
Protein expression and in vitro activity of caGM-CSF. Transfcction of COS cells for transicnt cxprcssion was pcrformcd with thc mammalian ccll cxprcssion vcctor pCMV/CAGM. Supcrnatant was collcctcd at 72 and 120 hours aftcr transfcction for analysis of activity. Biologic activity was asscsscd by adding supcrnatant from transfcctcd COS cclls cnrichcd for caGM-CSF at diffcrcnt dilutions to canine CFU-GM assays (Fig 4) . Culturc plates without any addition of growth factor or with supcrnatant from COS cclls that had not bccn transfcctcd scrvcd as two ncgativc controls. Platcs with 10% postcndotoxin dog serum or with human AB plasma wcrc thc positivc controls. Thc numbcr of CFU-GM colonies formcd in the caGM-CSF containing platcs was four-to scvenfold grcatcr than thc basclinc cstablishcd with the two ncgativc controls and cquivalcnt to thc numbers of colonics obtained with addition of postcndotoxin dog serum.
In vivo activity of caCM-CSF. Scvcn normal dogs wcrc treated with caGM-CSF to assess thc in vivo cffcct on hcmatopoicsis. Four dogs had a dosc schcdulc of 10 pgkg per day, and thrcc dogs had a dosc schcdulc of 1,30. or ncutrophil count as well as in thc lymphocyte and monocyte counts as compared with prctreatmcnt basclinc (Fig 5) . Thc mcan ncutrophil count at thc cnd of trcatmcnt for the four dogs rccciving 10 pg/kg per day was increased twofold over thc prctrcatmcnt bascline. The two dogs that rcccivcd highcr doses had grcatcr than fourfold increases in their ncutrophil counts. Thcrc was a suggcstion of an increase in thc absolute cosinophil count in thc PB but this was morc variablc and was unremarkable in thc dog receiving the dosc of 50 pglkg per day. Thc BM aftcr trcatmcnt appcarcd morc hypcrccllular at thc highcr dosc schcdulcs, and thcrc was cvidcncc of increased mitotic activity.
Thc platclct count startcd to dccrcasc within 24 hours of thc start of trcatmcnt (Fig 6) . Platelcts continucd to dccrcasc for 4 to 8 days of trcatment. At doscs of 1 and IO pgkg per day, counts started to increase while rccciving caGM-CSF. At the highcr doscs of 30 and 50 pgkg pcr day, platclct counts rcturncd to normal within several days aftcr caGM-CSF was discontinued, even increasing to above basclinc lcvcls. PB smcars showcd large platclcts with no morphologic abnormalitics, similar to the clinical syndromc of idiopathic thrombocytopcnia purpura. Examination of the marrows showcd that megakaryocytes wcrc cithcr normal or increased in frcqucncy. Platclct survival studies with "Cr-labclcd autologous platclcts wcrc performed in two dogs receiving doscs of 10 and 50 pgkg pcr day of caGM-CSF. Studics wcrc pcrformcd to establish thc normal survival curvcs of platclcts in cach animal as wcll as in thc first and sccond wcck of trcatmcnt. Thcsc studies showcd a dccrcascd survival of platclcts from about 5 to 6 days normally to 1.5 to 2.0 days.
DISCUSSION
Thc cDNA for caGM-CSF has been cloned and the polypcptidc cxprcsscd for in vitro and in vivo studies. The nuclcotidc scqucncc homology of thc open rcading framcs betwccn caGM-CSF and hGM-CSF is 80%. Thcrc is a 5' strctch 17 bp long, including the start codon, which is the same in all four of thc GM-CSF cDNAs from diffcrent spccics currcntly rcportcd.'.' " This may facilitate thc cloning of GM-CSF cDNAs from other specics. In the 3' untranslatcd region, thcrc is an AT-rich region with an ATTTA motif that has been described as destabilizing mRNA transcripts which may be important for regulation of GM-CSF. This motif is highly conserved in GM-CSF cDNA from different species.
The gene for caGM-CSF was shown to be a single copy in a Southern blot of restriction-digested caninc genomic DNA. The high degree of nuclcotide and amino acid sequence homology between GM-CSF and hGM-CSF as well as the obscrvation that this is a unique sequence in canine genomic DNA suggest that this molecule is indeed the canine homologue to hGM-CSF.
The in vitro biologic activity of the protein was confirmed by CFU-GM assays of canine marrow. The activity of caGM-CSF expressed from COS cells was similar to that of 10% postcndotoxin dog serum in canine CFU-GM assays. caGM-CSF has also been demonstrated to stimulate hGM-CSF-dcpcndcnt cell lines such as Tall 101, but other hGM-CSF-dependent cell lines may not be as responsive (D. Dale, unpublished observations, August 1990). hGM-CSF also stimulates in vivo canine hematopoiesis?' The cross-reactivity may be explained by the high degree of homology, especially in the region of 95 to 111 amino acids, which is another analogue for hGM-CSF that may be helpful in further defining regions of this molecule important for activity with human hematopoietic cells. The restricted GM-CSF activity between species that had been previously described seems less evident between canine and human forms.
When caGM-CSF was administered to normal dogs, there were increases in peripheral neutrophil, monocyte, and lymphocyte counts, with increased marrow cellularity. The change in eosinophil counts was more variable. Thrombocytopenia developed in all dogs and appeared to be dose-dependent. Normal to increased numbers of megakaryocytes in the BM and decreased platelet survival times implicated increased consumption as the mechanism. Whether production of platelets is affected is harder to determine, but the large platelets in the PB and the increase in platelet counts before caGM-CSF was discontinued at the lower dose level and the rapid rebound after caGM-CSF was discontinued at the higher dose level suggest some increased production. Increased production might be expected from direct or indirect stimulation of megakaryocytes by caGM-CSF or as a physiologic response to the thrombocytopenia. Thrombocytopenia also developed in dogs receiving hGM-CSF, and increased consumption was demonstrated as well by determining platelet survival times.38
The in vivo effect of GM-CSF on megakaryocytes and platelets is not well delineated. Platelet counts varied in different animal studies, with no changes observed in mice treated with murine GM-CSF" and platelets noted as unchanged, decreased, or increased in primates treated with hGM-CSF25,53 (A. Farese, unpublished observations, September 1990). Thrombocytopenia has been reported as a complication in several clinical studies of patients with cancer or acquired immunodeficiency syndrome receiving hGM-CSF.54.56 The possibility of exacerbation of an otherwise stable or subclinical autoimmune thrombocytopenia was considered for some patients. Patients with aplastic anemia were reported to have lower platelet counts 1 hour after platelet transfusion while being treated with hGM-CSF as compared with pretreatment increment^.^' Other studies have shown no significant change28 or, in some patients with myelodysplasia, an increase in platelet counts.29 There are reports of more rapid recovery of platelet count after autologous BMT.26,32
After PB counts, assessing the in vivo effect of GM-CSF on megakaryocytes and platelets is problematic because the platelet count is the result of a dynamic equilibrium between production and consumption of platelets. If GM-CSF increased both production and consumption of platelets, it could yield no change in peripheral counts, but some event such as a disease process or treatment could change the equilibrium and increase or decrease counts depending on the way in which production or consumption was effected. Studies on production and utilization of platelets will be necessary to assess the in vivo effects of GM-CSF. Assessment of the thrombocytopenia that develops in normal dogs with no predisposing factors may allow a better biologic description of an important side effect observed in some patients receiving hGM-CSF. This model may also be useful because this mechanism, by which thrombocytopenia may be induced directly or indirectly by abnormal amounts of a physiologic cytokine like GM-CSF, may also be operative in some disease processes.
caGM-CSF has been cloned and expressed and will be useful in analyzing questions about the in vivo biologic activities of GM-CSF in this animal model. It may also have therapeutic applications in veterinary practice to lessen hematologic toxicity of chemotherapy or as an adjuvant in treatment of infections. Thrombocytopenia is a reproducible dose-dependent phenomenon in normal dogs receiving species-specific GM-CSF. The decreased survival of platelets as a result of the in vivo administration of GM-CSF may also occur in other species, but other variables such as disease processes or chemotherapy may need to be operative to allow observation of significant changes in platelet counts.
